SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.
(深圳市海普瑞藥業集團股份有限公司)
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 9989)

VOLUNTARY ANNOUNCEMENT
"IVENOXIN" OBTAINS APPROVAL FROM SOUTH AFRICA

This announcement is made by Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the "**Company**", and together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business advancement of the Group.

The board of directors of the Company (the "**Board**") is pleased to announce that Ivenoxin (an enoxaparin sodium injection) produced by Shenzhen Techdow Medicine Co., Ltd., a wholly-owned subsidiary of the Company, has been approved by the South African Health Products Regulatory Authority (SAHPRA) for sale in the market:

DETAILS OF THE LICENSE

(I)	Product Name	:	Enoxaparin sodium injection
(II)	Registered Product Name	:	Ivenoxin
(III)	Dosage form	:	Injection
(IV)	Strength	:	0.2ml: 20mg, 0.4ml: 40mg, 0.6ml: 60mg, 0.8ml: 80mg, 1.0ml: 100mg
(V)	Indications	:	1. Prevention of thrombosis before and after surgery; 2. Reduction in the risk of thrombosis in patients with acute diseases that cause movement restrictions;

3. Treatment of deep vein thrombosis;

4. Combined with aspirin, reduction in the risk of complications after unstable angina (a condition of insufficient blood supply to the heart) or heart attack; and

5. Reduction in the risk of thrombosis in the tubing of hemodialysis machines (used for patients with severe kidney disease).

(VI) Validity period of the license : 5 years

BENEFIT AND IMPACT TO THE COMPANY

This approval means that the Group's enoxaparin sodium finish dose can be sold in the South African market, further enhancing the Group's market share of enoxaparin sodium finish dose worldwide. We believe that this approval is another important achievement in the international layout of the Group's finish dose business, once again proving the Group's ability to enter overseas markets. In the future, the Group will continue to exert efforts to accelerate the Group's expansion into the global market and the construction of sales channels, laying the groundwork for further strengthening the development of overseas markets.

As at the date of this announcement, the Group's enoxaparin sodium finish doses have been approved for sale in over 50 countries and regions around the world, including major markets such as China, United States, European Union, United Kingdom, Switzerland, Poland, Brazil, Colombia, Chile, Canada, Saudi Arabia, United Arab Emirates, Malaysia, Australia, New Zealand, Thailand and Argentina etc.

Announcement is hereby given.

By order of the Board
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Li Li
Chairman

Shenzhen, the PRC
April 24, 2025

As at the date of this announcement, the executive directors of the Company are Mr. Li Li, Ms. Li Tan, Mr. Shan Yu and Mr. Zhang Ping; and the independent non-executive directors of the Company are Dr. Lu Chuan, Mr. Huang Peng and Mr. Yi Ming.